The globaltheranostics marketSize is anticipated to reach over USD 20.52 Billion by 2026 according to a new study published by Polaris Market Research.
Theranostics are defined as a combination of diagnostics and drug therapeutics to improve the drug safety, drug restructures development and effectiveness. The combination of effective medical drugs and advanced diagnostic tests has been given numerous names, such as Dx/Rx partnering, integrated medicine, pharmacodiagnostics, and companion diagnostics.
危及生命和慢性疾病的发生增加以及与改善疾病检测需求相关的创新化学治疗治疗的需求是推进全球Theranostics市场的关键因素。此外，预计生物成像区域和治疗中临床适应性纳米材料的潜力的潜力将会加强市场增长。此外，预计药物和诊断公司之间的合作预计将增强Theranostics市场的增长。此外，药物段监测的医学试验所需的成本和减少时间是另一个推动全球Theranostics市场的增长的另一个关键助推器。
Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below:
//m.jiayuancx.com/industry-analysis/global-theranostics-market
全球Theranostics市场在疾病类型，技术和地理的基础上进行了分段。在疾病类型的基础上，全球Theranostics市场被分段为神经系统疾病，心血管疾病，肿瘤学疾病和免疫障碍。在疾病类型的基础上，预计肿瘤科学部门将提高市场增长。增加癌症病例和治疗症的潜力是有效的癌症护理是与市场增长相关的因素。在技术的基础上，全球Theranostics市场被分段为聚合酶链反应（PCR），原位杂交，免疫组化和测序。2017年，预计PCR将占据市场增长。在聚合酶链反应（PCR）方面存在稳健的评估品种对较大的市场份额负责。
Some major key players in global theranostics market include F Hoffman La Roche, Thermo Fisher Scientific Inc., GE Healthcare, Agilent Technologies, Qiagen NV, Foundation Medicine, Leica Biosystems Nussloch GmBH, and Pfizer, Inc. among others.